Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Atherosclerosis ; 236(1): 101-7, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25016364

ABSTRACT

OBJECTIVE: Elderly hypertensive patients are characterized by blood pressure (BP) variability, impaired autonomic function, and vascular endothelial dysfunction and stiffness. However, the mechanisms causing these conditions are unclear. The present study examined the effect of angiotensin receptor blockers (ARBs) on aged spontaneously hypertensive rats (SHR). METHODS: We surgically implanted telemetry devices in SHR and WKY at the age of 15 weeks (Young) and 80 weeks (Aged). Aged SHR were orally administered either olmesartan or valsartan once daily at 19:00 h (at the beginning of the dark period (active phase)) for 4 weeks to examine the effects on BP variability, impaired autonomic function, and vascular senescence. RESULTS: Aging and hypertension in SHR additively caused the following: increased low frequency (LF) power of systolic BP, a decreased spontaneous baroreceptor reflex gain (sBRG), increased BP variability, increased urinary norepinephrine excretion, increased vascular senescence-related beta-galactosidase positive cells and oxidative stress. Treatment with olmesartan or valsartan significantly ameliorated these changes in aged SHR. However, olmesartan ameliorated these changes in aged SHR better than valsartan. The reductions in BP caused by olmesartan in aged SHR were sustained longer than reductions by valsartan. This result indicates longer-lasting inhibition of the AT1 receptor by olmesartan than by valsartan. CONCLUSION: ARBs ameliorated autonomic dysfunction, BP variability, and vascular senescence in aged SHR. Olmesartan ameliorated the aging-related disorders better than valsartan and was associated with longer-lasting AT1 receptor inhibition by olmesartan. Thus, the magnitude of improvement of these aging-related abnormalities differs for ARBs.


Subject(s)
Aging/physiology , Angiotensin II Type 1 Receptor Blockers/therapeutic use , Autonomic Nervous System/drug effects , Blood Pressure/drug effects , Hypertension/drug therapy , Imidazoles/therapeutic use , Renin-Angiotensin System/drug effects , Tetrazoles/therapeutic use , Valine/analogs & derivatives , Angiotensin II Type 1 Receptor Blockers/administration & dosage , Angiotensin II Type 1 Receptor Blockers/pharmacology , Animals , Aorta/chemistry , Autonomic Nervous System/physiopathology , Baroreflex/drug effects , Blood Pressure/physiology , Drug Evaluation, Preclinical , Endothelium, Vascular/physiopathology , Hypertension/genetics , Hypertension/physiopathology , Imidazoles/administration & dosage , Imidazoles/pharmacology , Myocardium/pathology , NADPH Oxidases/analysis , NG-Nitroarginine Methyl Ester/pharmacology , Norepinephrine/urine , Organ Size/drug effects , Oxidative Stress , Rats , Rats, Inbred SHR , Rats, Inbred WKY , Reflex, Abnormal/drug effects , Renin-Angiotensin System/physiology , Tetrazoles/administration & dosage , Tetrazoles/pharmacology , Valine/administration & dosage , Valine/pharmacology , Valine/therapeutic use , Valsartan , Vasodilation/drug effects , Vasodilation/physiology , beta-Galactosidase/analysis
SELECTION OF CITATIONS
SEARCH DETAIL